Ashland has completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil, significantly enhancing its capabilities for coated tablets in Latin America and Brazil. The region has seen an average annual growth of 4.3% in coated tablet consumption, with Brazil reaching 5.7% per year. This investment supports the increasing market demand and strengthens Ashland's pharmaceutical footprint.
The expansion also includes the modernization of equipment for microbial protection in personal care applications at the company's Research and Development (R&D) laboratory in São Paulo. This follows previous investments in Ireland and China, demonstrating Ashland's strategy to globalize, innovate, and invest in key regions.
Guillermo Novo, Ashland's chair and chief executive officer, stated that these investments support the globalization of expertise in tablet coatings and microbial protection, ensuring more innovation and technical support for customers. The new capabilities enable customized solutions, ultra-high solids coatings, moisture protection, and modified release systems.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.